Navigation Links
CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
Date:11/7/2007

>ACR 50 7.6 38.0* 39.9*

ACR 70 3.5 21.2* 23.2*

Six and 12 month mean mTSS changes from baseline for RAPID 1

CIMZIA(R) CIMZIA(R)

(certolizumab (certolizumab

pegol) pegol)

Placebo & MTX 200mg & MTX 400mg & MTX

Six months 1.3 0.2* 0.2*

12 months 2.8 0.4* 0.2*

*p<0.001

In the six-month RAPID 2 trial, 619 patients were randomly allocated to receive one of three treatment regimens:

-- 246 patients received 400 mg formulation CIMZIA at the start of the

study and at weeks two and four, then 200 mg given every two weeks,

together with methotrexate;

-- 246 patients received 400 mg formulation CIMZIA every two weeks,

together with methotrexate;

-- 127 patients received placebo every two weeks, together with

methotrexate.

In all three arms of the study the dose of methotrexate was 10mg per week or greater. Patients were assessed for improvement in signs and symptoms of RA. The primary endpoint for the study RAPID 2 was ACR20 responder rate at week 24.

In both studies, CIMZIA given at a dosage of 200mg every two weeks was equally effective as a dosage of 400mg every two weeks.

Six month ACR Responses for RAPID 2

CIMZIA(R) CIMZIA(R)

(certolizumab (certolizumab

pegol) pegol)

Placebo & MTX 200mg & MTX 400mg & MTX

ACR 20 8.7 57.3
'/>"/>

SOURCE UCB
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
2. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
3. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
4. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
5. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
6. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
7. Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
8. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
9. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
10. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
11. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer ... Burbank , Chief Executive Officer, and Mathew Towse , ... Annual Canaccord Genuity Growth Conference being held at the InterContinental ... 13 th at 4:30 p.m. ET.  A webcast of ... About NxStage Medical NxStage Medical, ...
(Date:8/1/2014)... , Aug. 1, 2014  Neuland Laboratories Ltd., ... active pharmaceutical ingredients (APIs), complex intermediates and ... in 85 countries, today announced financial results for ... ended June 30, 2014. "Neuland,s results ... flow re-prioritization to accommodate certain customer needs, and ...
(Date:8/1/2014)... Aug. 1, 2014 Dyadic International, Inc. ("Dyadic") ... proprietary technologies are used to develop, manufacture and sell ... biopharmaceutical and industrial enzyme industries, announced today that it ... ended June 30, 2014 after market close on Thursday, ... that day at 5:00 p.m. Eastern Time to discuss ...
Breaking Medicine Technology:NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 3Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3
... Second Generation Oxazolidinone Demonstrates Safety and Efficacy with Once-Daily, ... of Treatment , , SAN DIEGO, June ... its Phase 2 clinical trial evaluating the safety and ... the treatment of severe complicated skin and skin structure ...
... sets to be released-- , , PARIS, ... in patients with blepharospasm and cervical dystonia -- one placebo-controlled ... presented at the Movement Disorder Society (MDS) 13th annual International ... Pharmaceuticals, which plans to file a Biologic License Application (BLA) ...
Cached Medicine Technology:Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections 2Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections 3Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections 4Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 2Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 3Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 4
(Date:8/1/2014)... The brain plays a central role in regulating appetite ... important in the brain,s control of food intake and ... this process has been unclear. A new ... demonstrates that PPARγ activity in a type of neuron ... the response to high-fat diet. Sabrina Diano and ...
(Date:8/1/2014)... HealthDay Reporter FRIDAY, Aug. 1, 2014 (HealthDay ... may have significantly less endurance than those who weigh less, a ... half were obese, half were of normal weight -- people who ... longer. Obesity also was associated with less strength, increased discomfort ... 50 to 65 years of age -- neither improved nor reduced ...
(Date:8/1/2014)... U.S. Food and Drug Administration announced on Friday that ... type 2 diabetes. Jardiance (empagliflozin) "can be ... control blood sugar levels in the overall management of ... Drug Evaluation II in the FDA,s Center for Drug ... The FDA also recommended that Jardiance be used along ...
(Date:8/1/2014)... a first-of-its-kind study, researchers at University Hospitals Rainbow Babies ... may be at greater risk for death on a ... on flights worldwide between January 2010 and June 2013 ... under the age of 2. , The study ... rare event of an in-flight pediatric fatality onboard commercial ...
(Date:8/1/2014)... August 01, 2014 Summer is here, and ... active during the summer, and they can be a pain ... ready to help all their customers get rid of ticks ... and 6,000 eggs in the summer, which is why they ... in tall grass and woodland areas and carry a number ...
Breaking Medicine News(10 mins):Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:New research characterizes in-flight pediatric deaths 2Health News:Tis the Season for Tick Prevention 2
... ROCM ) will announce quarterly results after,financial markets ... hold a quarterly conference call to discuss its earnings ... (5:00 p.m. eastern time)., This call is being ... website at http://www.rocm.com . To listen live to ...
... China, Oct. 28 /Xinhua-PRNewswire-FirstCall/ -- China Sky ... "the Company") (Nasdaq: CSKI ), a,leading ... the People,s Republic of China ("PRC"), announced ... purchase a proprietary breast drug from,Harbin Medical ...
... The Los Angeles Shambhala Center,presents a public talk and Zen ... 30 and November 1st and 2nd., This 20th generation ... the first time in Los Angeles at the Shambhala Meditation ... Colorado Blvd.,in Eagle Rock., On Thursday, October 30th, Shibata ...
... 28 /PRNewswire-FirstCall/ - Response Biomedical,Corporation (TSX: RBM, OTCBB: ... an initial closing of the financing announced on ... raising gross proceeds of $4.66,million. The closing involved ... at a price of $0.15 for each unit. ...
... series, Debating Health: Election 2008, the Harvard Public Opinion Research ... Harris Interactive conducted a new survey focused on whether voters ... great deal of difference" in the state of the nation,s ... been made of voter cynicism in recent times, a majority ...
... that was 29 days or older faced twice the risk ... receive a transfusion of stored blood that is 29 days ... more serious infections compared to those who get "fresher" blood, ... current U.S. regulations set the upper limit for blood storage ...
Cached Medicine News:Health News:Rochester Medical Announces Fourth Quarter 2008 Earnings Conference Call November 6, 2008 2Health News:China Sky One Medical, Inc. Acquires Drug to Treat Breast Lesions 2Health News:China Sky One Medical, Inc. Acquires Drug to Treat Breast Lesions 3Health News:Renowned Kyudo (Zen archery) Master Kanjuro Shibata Sensei to Present in L.A. 2Health News:Response Biomedical Completes Initial Closing of an expected $5.0 Million Financing 2Health News:Response Biomedical Completes Initial Closing of an expected $5.0 Million Financing 3Health News:Response Biomedical Completes Initial Closing of an expected $5.0 Million Financing 4Health News:Majority of voters say election outcome will make a great deal of difference on key issues 2Health News:Majority of voters say election outcome will make a great deal of difference on key issues 3Health News:Older Blood Boosts Chances of Infection in Transfusion Patients 2Health News:Older Blood Boosts Chances of Infection in Transfusion Patients 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: